Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
Clinical trial NCT00408967 · WITHDRAWN
Trial details
- NCT number
- NCT00408967
- Sponsor
- EMD Serono
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-12-31
- Primary completion
- 2008-05-31
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.